[go: up one dir, main page]

MX9701342A - Formulacion cosolvente de tirilazad para administracion parenteral. - Google Patents

Formulacion cosolvente de tirilazad para administracion parenteral.

Info

Publication number
MX9701342A
MX9701342A MX9701342A MX9701342A MX9701342A MX 9701342 A MX9701342 A MX 9701342A MX 9701342 A MX9701342 A MX 9701342A MX 9701342 A MX9701342 A MX 9701342A MX 9701342 A MX9701342 A MX 9701342A
Authority
MX
Mexico
Prior art keywords
cosolvent
tirilazad
parenteral formulation
parenteral
formulation
Prior art date
Application number
MX9701342A
Other languages
English (en)
Inventor
Ching-Chiang Su
David S Baker
Susan M Machkovech
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MX9701342A publication Critical patent/MX9701342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invencion se refiere a una formulacion farmacéutica cosolvente para administracion parenteral de un lazariode y sus sales farmacéuticamente aceptables.
MX9701342A 1994-09-01 1995-08-29 Formulacion cosolvente de tirilazad para administracion parenteral. MX9701342A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29937094A 1994-09-01 1994-09-01
US38225695A 1995-02-01 1995-02-01
PCT/US1995/010730 WO1996006618A1 (en) 1994-09-01 1995-08-29 Cosolvent parenteral formulation of tirilazad

Publications (1)

Publication Number Publication Date
MX9701342A true MX9701342A (es) 1997-05-31

Family

ID=26971187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701342A MX9701342A (es) 1994-09-01 1995-08-29 Formulacion cosolvente de tirilazad para administracion parenteral.

Country Status (23)

Country Link
US (1) US5858999A (es)
EP (1) EP0778775B1 (es)
JP (1) JPH10505063A (es)
KR (1) KR100359556B1 (es)
CN (1) CN1156962A (es)
AT (1) ATE175875T1 (es)
AU (1) AU696856B2 (es)
BR (1) BR9508655A (es)
CA (1) CA2196063A1 (es)
CZ (1) CZ283875B6 (es)
DE (1) DE69507493T2 (es)
DK (1) DK0778775T3 (es)
ES (1) ES2128761T3 (es)
FI (1) FI970858A0 (es)
GR (1) GR3029396T3 (es)
HU (1) HUT76808A (es)
MX (1) MX9701342A (es)
NO (1) NO311405B1 (es)
NZ (1) NZ292690A (es)
PL (1) PL181244B1 (es)
RU (1) RU2152789C2 (es)
SK (1) SK280278B6 (es)
WO (1) WO1996006618A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254564B1 (en) 1998-09-10 2001-07-03 Percardia, Inc. Left ventricular conduit with blood vessel graft
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
ES2232195T3 (es) * 1999-01-28 2005-05-16 Dinesh Shantilal Patel Solucion parenteral de propofol (2,6-diisopropilfenol) y 2,5-di-o-metil-1,4;3,6-dianhidro-d-glucitol como solvente.
DE10010073B4 (de) 2000-02-28 2005-12-22 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verankerung für implantierbare Herzklappenprothesen
DE10010074B4 (de) 2000-02-28 2005-04-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung zur Befestigung und Verankerung von Herzklappenprothesen
FR2828263B1 (fr) 2001-08-03 2007-05-11 Philipp Bonhoeffer Dispositif d'implantation d'un implant et procede d'implantation du dispositif
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2550459C (en) * 2003-12-18 2009-12-15 Biomas, Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
CA2580643C (en) 2004-09-17 2018-06-12 Biomas, Ltd. Use of tellurium compounds for inhibition of interleukin-converting enzyme
CA2582231A1 (en) * 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
DE102005051849B4 (de) 2005-10-28 2010-01-21 JenaValve Technology Inc., Wilmington Vorrichtung zur Implantation und Befestigung von Herzklappenprothesen
DE102005052628B4 (de) 2005-11-04 2014-06-05 Jenavalve Technology Inc. Selbstexpandierendes, flexibles Drahtgeflecht mit integrierter Klappenprothese für den transvaskulären Herzklappenersatz und ein System mit einer solchen Vorrichtung und einem Einführkatheter
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US9295551B2 (en) 2007-04-13 2016-03-29 Jenavalve Technology Gmbh Methods of implanting an endoprosthesis
US9138315B2 (en) 2007-04-13 2015-09-22 Jenavalve Technology Gmbh Medical device for treating a heart valve insufficiency or stenosis
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US8317858B2 (en) 2008-02-26 2012-11-27 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8398704B2 (en) 2008-02-26 2013-03-19 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US8465540B2 (en) 2008-02-26 2013-06-18 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis
US9168130B2 (en) 2008-02-26 2015-10-27 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
JP5780521B2 (ja) 2008-05-28 2015-09-16 リベラジェン・バイオファーマ・インコーポレイテッドＲｅｖｅｒａＧｅｎ ＢｉｏＰｈａｒｍａ，Ｉｎｃ． 疾患を治療するための、ＮＦ−κＢの非ホルモン性ステロイド調節因子
US8468667B2 (en) 2009-05-15 2013-06-25 Jenavalve Technology, Inc. Device for compressing a stent
EP2556083A4 (en) 2010-04-05 2013-12-04 Validus Biopharma Inc NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT
US11278406B2 (en) 2010-05-20 2022-03-22 Jenavalve Technology, Inc. Catheter system for introducing an expandable heart valve stent into the body of a patient, insertion system with a catheter system and medical device for treatment of a heart valve defect
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
CA2852369A1 (en) 2011-10-21 2013-04-25 Jenavalve Technology Inc. Catheter system for introducing an expandable heart valve stent into the body of a patient, insertion system with a catheter system and medical device for treatment of a heart valve defect
JP6227632B2 (ja) 2012-05-16 2017-11-08 イェーナヴァルヴ テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 拡張可能心臓代用弁を導入するためのカテーテル送達システムおよび心臓弁欠陥の治療のための医療デバイス
CN103861090B (zh) * 2012-12-18 2017-06-13 美迪思生物科技(北京)有限公司 含蛋白或多肽的疏水溶液、其制备方法及用途
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
WO2016150806A1 (en) 2015-03-20 2016-09-29 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath
EP3288495B1 (en) 2015-05-01 2019-09-25 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
JP7081749B2 (ja) 2016-05-13 2022-06-07 イエナバルブ テクノロジー インク 心臓弁プロテーゼ送達システム
WO2018138658A1 (en) 2017-01-27 2018-08-02 Jenavalve Technology, Inc. Heart valve mimicry
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61501566A (ja) * 1984-03-14 1986-07-31 コルビエ−ル　ジエロ−ム 有効成分の可溶化法およびそれにより得られる薬理組成物
US5175281A (en) * 1985-09-12 1992-12-29 The Upjohn Company Pharmaceutically active pyrimidinylpiperazinylsterioids
WO1987001706A2 (en) * 1985-09-12 1987-03-26 The Upjohn Company C20 through c26 amino steroids
US4968675A (en) * 1988-10-28 1990-11-06 Upjohn Non-hemolytic lazaroid parenteral formulation
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
JP2002500616A (ja) * 1994-07-21 2002-01-08 ファルマシア・アンド・アップジョン・カンパニー 神経学的に活性なアミノステロイド
US5614515A (en) * 1994-11-17 1997-03-25 University Of Southern California Lazaroid-based compositions and method for preventing adhesion formation using the same

Also Published As

Publication number Publication date
SK280278B6 (sk) 1999-10-08
FI970858A7 (fi) 1997-02-28
KR100359556B1 (ko) 2002-12-18
CA2196063A1 (en) 1996-03-07
GR3029396T3 (en) 1999-05-28
AU696856B2 (en) 1998-09-17
NZ292690A (en) 1998-06-26
US5858999A (en) 1999-01-12
WO1996006618A1 (en) 1996-03-07
DE69507493D1 (de) 1999-03-04
NO970935D0 (no) 1997-02-28
DK0778775T3 (da) 1999-09-13
CZ55997A3 (en) 1997-06-11
BR9508655A (pt) 1997-08-12
NO311405B1 (no) 2001-11-26
NO970935L (no) 1997-04-11
SK26297A3 (en) 1997-09-10
CN1156962A (zh) 1997-08-13
PL318901A1 (en) 1997-07-21
HUT76808A (en) 1997-11-28
JPH10505063A (ja) 1998-05-19
FI970858L (fi) 1997-02-28
CZ283875B6 (cs) 1998-06-17
ES2128761T3 (es) 1999-05-16
FI970858A0 (fi) 1997-02-28
PL181244B1 (pl) 2001-06-29
RU2152789C2 (ru) 2000-07-20
EP0778775B1 (en) 1999-01-20
DE69507493T2 (de) 1999-06-10
EP0778775A1 (en) 1997-06-18
ATE175875T1 (de) 1999-02-15
AU3493895A (en) 1996-03-22

Similar Documents

Publication Publication Date Title
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
HN2000000224A (es) Aminoacidos biciclicos como agentes farmaceuticos
AR027162A1 (es) Compuestos de 2-fenil-3-fenoxilo-feniltio-benzotiofeno, sales farmaceuticamente aceptables de los mismos y composiciones farmaceuticas que los contienen
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
MY115662A (en) Novel compounds with analgesic effect
BR9607862A (pt) Composição farmacêutica filmogênica para administração transdérmica
SE9503143D0 (sv) New preparation
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
FI950947L (fi) Oraalisesti annettavat farmaseuttiset formulaatiot
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
BR0012901A (pt) Medicamentos de ß - carbolina
FR2735369B1 (fr) Compositions pharmaceutiques a base de sel de sodium du diclofenac et de thiocolchicoside
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.
PT835103E (pt) Nanoparticulas para administracao oral de agentes farmaceuticos de baixa solubilidade
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ES2064166T3 (es) Composiciones conteniendo propionato de fluticasona y oxiconazol o sus sales para administracion topica.
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DE69525649D1 (de) Lamotrigin haltiges arzneimittel
MX9300399A (es) Derivados heterotriciclicos.
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
SE9504662D0 (sv) New compounds
AR004503A1 (es) Uso de l-carnitina, l-carnitinas acilicas en las cuales el gruo acilo, lineal o ramificado, tiene entre 2 y 6 atomos de carbono y sus salesfarmaceuticamente aceptables, y composiciones farmaceuticas que comprenden tales compuestos
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.